These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34938127)

  • 1. Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A Japanese Experience.
    Roshmi RR; Yokota T
    Clin Pharmacol; 2021; 13():235-242. PubMed ID: 34938127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viltolarsen: From Preclinical Studies to FDA Approval.
    Roshmi RR; Yokota T
    Methods Mol Biol; 2023; 2587():31-41. PubMed ID: 36401022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viltolarsen for the treatment of Duchenne muscular dystrophy.
    Roshmi RR; Yokota T
    Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viltolarsen: First Approval.
    Dhillon S
    Drugs; 2020 Jul; 80(10):1027-1031. PubMed ID: 32519222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viltolarsen: a treatment option for Duchenne muscular dystrophy patients who are amenable to exon 53 skipping therapy.
    Czifrus E; Berlau DJ
    Expert Rev Neurother; 2023; 23(10):853-858. PubMed ID: 37572081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Golodirsen for Duchenne muscular dystrophy.
    Anwar S; Yokota T
    Drugs Today (Barc); 2020 Aug; 56(8):491-504. PubMed ID: 33025945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy.
    Vincik LY; Dautel AD; Staples AA; Lauck LV; Armstrong CJ; Howard JT; McGregor D; Ahmadzadeh S; Shekoohi S; Kaye AD
    Adv Ther; 2024 Apr; 41(4):1338-1350. PubMed ID: 38376743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
    JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Evaluation of Exon 51 Skipping in hDMD/Dmd-null Mice.
    Sheri N; Yokota T
    Methods Mol Biol; 2023; 2640():327-336. PubMed ID: 36995605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; McDonald CM; Smith EC; Zaidman CM; Nakagawa T; ; Hoffman EP
    J Neuromuscul Dis; 2022; 9(4):493-501. PubMed ID: 35634851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; McDonald CM; Smith EC; Zaidman CM; Nakagawa T; ; Hoffman EP
    J Neuromuscul Dis; 2023; 10(3):439-447. PubMed ID: 37005891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.
    Echigoya Y; Lim KRQ; Melo D; Bao B; Trieu N; Mizobe Y; Maruyama R; Mamchaoui K; Tanihata J; Aoki Y; Takeda S; Mouly V; Duddy W; Yokota T
    Mol Ther; 2019 Nov; 27(11):2005-2017. PubMed ID: 31416775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMD.
    Akpulat U; Wang H; Becker K; Contreras A; Partridge TA; Novak JS; Cirak S
    Mol Ther Nucleic Acids; 2018 Dec; 13():534-542. PubMed ID: 30396145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in
    Gan L; Wu LCL; Wood JA; Yao M; Treleaven CM; Estrella NL; Wentworth BM; Hanson GJ; Passini MA
    Mol Ther Nucleic Acids; 2022 Dec; 30():17-27. PubMed ID: 36189424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
    Maruyama R; Aoki Y; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.